M Bangerter

Summary

Country: Germany

Publications

  1. pmc A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011
  2. ncbi request reprint [Medical treatment of cancer in the elderly]
    M Bangerter
    Hämatologisch onkologische Gemeinschafts Praxis, Augsburg
    MMW Fortschr Med 146:30-2. 2004
  3. ncbi request reprint Fine needle aspiration cytology and flow cytometry in the diagnosis and subclassification of non-Hodgkin's lymphoma based on the World Health Organization classification
    Markus Bangerter
    Hematological and Oncological Practice, Augsburg, Germany
    Acta Cytol 51:390-8. 2007
  4. ncbi request reprint Open or closed nuclear membrane? A question to help distinguish malignant lymphoma from carcinoma and sarcoma
    Markus Bangerter
    Hematology and Oncology Practice, Augsburg, Germany
    Acta Cytol 52:52-5. 2008
  5. ncbi request reprint Cytomorphologic pitfall of primary malignant melanoma of the parotid gland: a case report
    Markus Bangerter
    Hematology and Oncology Practice, Augsburg, Germany
    Acta Cytol 53:435-6. 2009
  6. ncbi request reprint 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease
    Martin Wagner
    Department of Nuclear Medicine, University of Ulm, 89081 Ulm, Germany
    Cancer Res 63:2681-7. 2003
  7. ncbi request reprint Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia
    Alexander Kröber
    Department of Internal Medicine, University of Ulm, Ulm, Germany
    J Clin Oncol 24:969-75. 2006

Collaborators

  • Martin Griesshammer
  • B Heinrich
  • Andreas K Buck
  • Sven N Reske
  • Clemens Giessen
  • Alexander Kröber
  • Martin Wagner
  • Markus Sieber
  • Nicolas Moosmann
  • Ursula Vehling-Kaiser
  • Christoph Schulz
  • Jens Freiberg-Richter
  • Axel Hinke
  • Ludwig Fischer von Weikersthal
  • Volker Heinemann
  • Julia Mayerle
  • Claudio Denzlinger
  • Frank Kullmann
  • Philipp Aubele
  • Dominik Paul Modest
  • Sebastian Stintzing
  • Christian Teschendorf
  • Sebastian Hafner
  • Richard F Schlenk
  • Stephan Stilgenbauer
  • Till Seiler
  • Dirk Kienle
  • Johannes Bloehdorn
  • Hartmut Dohner
  • Dirk Winkler
  • Axel Benner
  • Andreas Bühler
  • Peter Lichter
  • Bernd Neumaier
  • Ulrike Seitz
  • Frank Leithäuser
  • Gerd Munzert
  • Martin Bommer
  • Edgar Wawra
  • Stefan Schultheiss

Detail Information

Publications7

  1. pmc A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011
    ..The present study investigates the question whether this statement holds true also for bevacizumab-based first-line treatment including escalation- and de-escalation strategies...
  2. ncbi request reprint [Medical treatment of cancer in the elderly]
    M Bangerter
    Hämatologisch onkologische Gemeinschafts Praxis, Augsburg
    MMW Fortschr Med 146:30-2. 2004
    ....
  3. ncbi request reprint Fine needle aspiration cytology and flow cytometry in the diagnosis and subclassification of non-Hodgkin's lymphoma based on the World Health Organization classification
    Markus Bangerter
    Hematological and Oncological Practice, Augsburg, Germany
    Acta Cytol 51:390-8. 2007
    ..To determine the usefulness of fine needle aspiration cytology (FNAC) in combination with flow cytometry on the new World Health Organization (WHO) classification of malignant lymphoma...
  4. ncbi request reprint Open or closed nuclear membrane? A question to help distinguish malignant lymphoma from carcinoma and sarcoma
    Markus Bangerter
    Hematology and Oncology Practice, Augsburg, Germany
    Acta Cytol 52:52-5. 2008
    ..To describe a cytomorphologic criterion that may help improve diagnostic safety in morphologic differentiation of non-Hodgkin's lymphoma (NHL) from carcinoma or sarcoma and investigate the significance of this cytomorphologic phenomenon...
  5. ncbi request reprint Cytomorphologic pitfall of primary malignant melanoma of the parotid gland: a case report
    Markus Bangerter
    Hematology and Oncology Practice, Augsburg, Germany
    Acta Cytol 53:435-6. 2009
    ..Primary malignant melanoma of the salivary gland is a rare disease, and only afew cases describing FNAC have been reported...
  6. ncbi request reprint 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease
    Martin Wagner
    Department of Nuclear Medicine, University of Ulm, 89081 Ulm, Germany
    Cancer Res 63:2681-7. 2003
    ..These results suggest that [(18)F]-FLT represents a novel tracer for PET that enables imaging of proliferation in human lymphoma in vivo...
  7. ncbi request reprint Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia
    Alexander Kröber
    Department of Internal Medicine, University of Ulm, Ulm, Germany
    J Clin Oncol 24:969-75. 2006
    ..The goal of this study was to elucidate additional factors potentially characterizing their discordance...